Patents by Inventor Stepan Vyskocil

Stepan Vyskocil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190255052
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: September 19, 2018
    Publication date: August 22, 2019
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Steven P. LANGSTON, Edward J. OLHAVA, Stepan VYSKOCIL
  • Patent number: 10323018
    Abstract: This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 18, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Brian Scott Freeze, Kenneth M. Gigstad, David A. Janowick, Hong Myung Lee, Zhan Shi, Francois Soucy, Stepan Vyskocil
  • Patent number: 10144742
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 4, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • Patent number: 10016427
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: July 10, 2018
    Assignee: Millennium Pharmacetuicals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Publication number: 20180009784
    Abstract: This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.
    Type: Application
    Filed: January 20, 2016
    Publication date: January 11, 2018
    Inventors: Brian Scott Freeze, Kenneth M. Gigstad, David A. Janowick, Hong Myung Lee, Zhan Shi, Francois Soucy, Stepan Vyskocil
  • Patent number: 9718788
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 1, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil
  • Publication number: 20170174704
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Application
    Filed: April 17, 2015
    Publication date: June 22, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • Publication number: 20170136024
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: July 20, 2016
    Publication date: May 18, 2017
    Inventors: Steven P. Langston, Edward J. OLHAVA, Stepan VYSKOCIL
  • Publication number: 20170050935
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 29, 2016
    Publication date: February 23, 2017
    Inventors: Christopher F. CLAIBORNE, Stephen CRITCHLEY, Courtney A. CULLIS, Steven P. LANGSTON, Hirotake MIZUTANI, Edward J. OLHAVA, Stephane PELUSO, lrache VISIERS, Stepan VYSKOCIL, Gabriel S. WEATHERHEAD
  • Publication number: 20170000792
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Application
    Filed: October 9, 2015
    Publication date: January 5, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Patent number: 9458108
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: October 4, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
  • Publication number: 20160039761
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 17, 2015
    Publication date: February 11, 2016
    Inventors: Christopher F. CLAIBORNE, Stephen CRITCHLEY, Courtney A. CULLIS, Steven P. LANGSTON, Hirotake MIZUTANI, Edward J. OLHAVA, Stephane PELUSO, lrache VISIERS, Stepan VYSKOCIL, Gabriel S. WEATHERHEAD
  • Publication number: 20160030432
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Application
    Filed: October 9, 2015
    Publication date: February 4, 2016
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Patent number: 9187482
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: November 17, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • Patent number: 9150525
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: October 6, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
  • Patent number: 9139589
    Abstract: This invention provides compounds of formula IA or IB: wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: September 22, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Masaaki Hirose, Steven P. Langston, Hirotake Mizutani, Stepan Vyskocil
  • Publication number: 20150183753
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: September 8, 2014
    Publication date: July 2, 2015
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Publication number: 20150175563
    Abstract: This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof: wherein Z, HY, R1, R2, R3, G1, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 25, 2015
    Inventors: Brian S. Freeze, Masaaki Hirose, Yongbo Hu, Todd B. Sells, Zhan Shi, Stepan Vyskocil, Tianlin Xu
  • Publication number: 20150175593
    Abstract: This invention provides compounds of formula IA-a or IB-a and subsets thereof: wherein Z, HY, R1, R2, G1, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 25, 2015
    Inventors: Masaaki Hirose, Zhigen Hu, Yongbo Hu, Hong Myung Lee, Zhan Shi, Stepan Vyskocil, Tianlin Xu
  • Patent number: 9062038
    Abstract: This invention provides compounds of formula IA or IB: wherein HY, R1, R2, G1, W, n, and A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: June 23, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Masaaki Hirose, Yongbo Hu, Zhigen Hu, Hong Myung Lee, Zhan Shi, Stepan Vyskocil, Tianlin Xu